Abstract
Background: Alpha interferon (IFN) alone or in combination with Ribavirin (RBV) is the treatment of choice for HCV related chronic liver disease. There are many types of alpha IFN and to date only few reports are available comparing different types of alpha interferon. We run a randomised controlled trial with the aim to compare tolerability and efficacy of two different types of IFN: recombinant alpha 2b interferon (IFN-R) and leukocyte alpha n-3 interferon (IFN-L) at the same dosage of 3 MU subcutaneously thrice weekly for one year. Methods: one hundred sixty eight consecutive anti-HCV positive naive patients, 34 mild chronic active hepatitis (MCH), 81 moderate-severe hepatitis (MSCR) and 53 active cirrhosis (CIRR) that met the inclusion criteria were enrolled into the study. The diagnosis of HCV chronic liver disease was established by liver biopsy performed on patients with abnormal serum alanine aminotransferase (ALT) value for at least one year. HCV serology: all patients were tested for confirmatory test RIBA II, HCV-RNA, and identification of viral genotype. Patients were randomised to receive either IFN-R or IFN-L. Follow-up continued for at least two years after stopping treatment. Results: no significant differences were observed between the two groups of treatment as far as the incidence of side effects is concerned. Tolerability was good: only 11 in IFN-R and 8 patients IFN-L group respectively had to stop therapy due to side effects. The two types of IFN showed a comparable efficacy: an end of therapy response was observed in 34% of IFN-R and 30% of IFN-L patients; a sustained response was seen in 16% of IFN-R and in 19% of IFN-L patients. Conclusion: in the treatment of patients with chronic hepatitis C there was no statistically significant difference in tolerability and efficacy between the two IFNs tested.
Keywords: recombinant alpha, leurocyte interferon, chc, mch, mscr, cirr
Current Pharmaceutical Design
Title: Incidence of Side Effects During Therapy with Different Types of Alpha Interferon: A Randomised Controlled Trial Comparing Recombinant Alpha 2b Versus Leukocyte Interferon in the Therapy of Naive Patients with Chronic Hepatitis C
Volume: 8 Issue: 11
Author(s): Antonio Ascione, Massimo De Luca, Giovan Giuseppe Di Costanzo, Francesco aolo Picciotto, Alfonso Galeota Lanza, Carmine Canestrini, Filomena Morisco, Concetta Tuccillo and Nicola Caporaso
Affiliation:
Keywords: recombinant alpha, leurocyte interferon, chc, mch, mscr, cirr
Abstract: Background: Alpha interferon (IFN) alone or in combination with Ribavirin (RBV) is the treatment of choice for HCV related chronic liver disease. There are many types of alpha IFN and to date only few reports are available comparing different types of alpha interferon. We run a randomised controlled trial with the aim to compare tolerability and efficacy of two different types of IFN: recombinant alpha 2b interferon (IFN-R) and leukocyte alpha n-3 interferon (IFN-L) at the same dosage of 3 MU subcutaneously thrice weekly for one year. Methods: one hundred sixty eight consecutive anti-HCV positive naive patients, 34 mild chronic active hepatitis (MCH), 81 moderate-severe hepatitis (MSCR) and 53 active cirrhosis (CIRR) that met the inclusion criteria were enrolled into the study. The diagnosis of HCV chronic liver disease was established by liver biopsy performed on patients with abnormal serum alanine aminotransferase (ALT) value for at least one year. HCV serology: all patients were tested for confirmatory test RIBA II, HCV-RNA, and identification of viral genotype. Patients were randomised to receive either IFN-R or IFN-L. Follow-up continued for at least two years after stopping treatment. Results: no significant differences were observed between the two groups of treatment as far as the incidence of side effects is concerned. Tolerability was good: only 11 in IFN-R and 8 patients IFN-L group respectively had to stop therapy due to side effects. The two types of IFN showed a comparable efficacy: an end of therapy response was observed in 34% of IFN-R and 30% of IFN-L patients; a sustained response was seen in 16% of IFN-R and in 19% of IFN-L patients. Conclusion: in the treatment of patients with chronic hepatitis C there was no statistically significant difference in tolerability and efficacy between the two IFNs tested.
Export Options
About this article
Cite this article as:
Ascione Antonio, Luca De Massimo, Costanzo Giuseppe Di Giovan, Picciotto aolo Francesco, Lanza Galeota Alfonso, Canestrini Carmine, Morisco Filomena, Tuccillo Concetta and Caporaso Nicola, Incidence of Side Effects During Therapy with Different Types of Alpha Interferon: A Randomised Controlled Trial Comparing Recombinant Alpha 2b Versus Leukocyte Interferon in the Therapy of Naive Patients with Chronic Hepatitis C, Current Pharmaceutical Design 2002; 8 (11) . https://dx.doi.org/10.2174/1381612024607018
DOI https://dx.doi.org/10.2174/1381612024607018 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Complement and Complement Regulatory Proteins as Potential Molecular Targets for Vascular Diseases
Current Pharmaceutical Design Tumor Necrosis Factor: How to Make a Killer Molecule Tumor-Specific?
Current Cancer Drug Targets Role of Mitochondria on Muscle Cell Death and Meat Tenderization
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Preface [Hot Topic: Advances in the Treatment of Hepatitis B and C Virus Infections (Executive Editor: Raffaele Cozzolongo)]
Current Pharmaceutical Design The Virus Infection and Biliary Atresia
Current Pediatric Reviews Fish and Apoptosis: Molecules and Pathways
Current Pharmaceutical Design Homeostasis and the Importance for a Balance Between AKT/mTOR Activity and Intracellular Signaling
Current Medicinal Chemistry Milk Donor Blood Screening for HIV, Syphilis and Hepatitis B Markers in a Brazilian Human Milk Bank: Prevalence Time-trends Over the 2005- 2015 Period
Current HIV Research Safety of Canagliflozin in Patients with Type 2 Diabetes
Current Drug Safety Design and Synthesis of Pterin Derivares as Nitric Oxide Synthase Inhibitors
Letters in Drug Design & Discovery Incidence of Profound Hypogammaglobulinemia and Infection Rate in Lymphoma Patients Following the Combination of Chemotherapy and Rituximab
Recent Patents on Anti-Cancer Drug Discovery Pharmacogenomics in Psychiatry: Implications for Practice
Recent Patents on Biotechnology Searching for Phytoinsulins as Cardiovascular Protector in Metabolic Syndrome
Current Pharmaceutical Design Back Pain in Children and Adolescents: Etiology, Clinical Approach and Treatment
Current Pediatric Reviews Activities of Quinolones Against Obligately Anaerobic Bacteria
Anti-Infective Agents in Medicinal Chemistry Resveratrol as a Chemopreventive Agent: A Promising Molecule for Fighting Cancer
Current Drug Targets Targeting Interferon Regulatory Factor for Cardiometabolic Diseases: Opportunities and Challenges
Current Drug Targets The TCR/CD3 Complex: Opening the Gate to Successful Vaccination
Current Pharmaceutical Design The Combination of Chrysin and Cisplatin Induces Apoptosis in HepG2 through Down-regulation of cFLIP and Activity of Caspase
Anti-Cancer Agents in Medicinal Chemistry Anti-Infective Quinone Derivatives of Recent Patents
Recent Patents on Anti-Infective Drug Discovery